Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Tuesday, July 28, 2026

Dad Had Manuals, I Have An Agent

›
My father was a very methodical person, and that particularly applied when he decided to purchase the second IBM PC clone to appear on the m...
Tuesday, July 21, 2026

Element's Curious Patentsieg

›
Last week news broke that Element Biosciences had won a patent lawsuit against Illumina, and that it affected MiSeq.  MiSeq????  How did a p...
Monday, July 20, 2026

Fiber-Seq: Plasmids Model Chromosomes Well

›
A recent publication in Molecular Cell involving Fiber-Seq caught my attention, though I've since discovered this preprinted over a yea...
Friday, July 10, 2026

The Simulator That Isn't There

›
Okay, this is one of those cases where I kvetch about other people not having built the tools I want to use - perhaps a bit of a insufferabl...
Tuesday, July 07, 2026

Countable Labs Raises Funds, Heads to Clinic

›
I caught up by teleconference recently with Countable Labs CEO Giovanna Prout, fresh off Countable Labs' $26M equity fundraising - a rou...
Sunday, June 28, 2026

Alex Hastie Returns to BioNano, Takes CSO Reins

›
An interesting news item this week is that BioNano Genomics has appointed Alex Hastie as Chief Scientific Officer.  Hastie is an obvious cho...
2 comments:
Wednesday, June 24, 2026

E.coli Doesn't Like Diets Either, At Least Genomic Ones

›
Another interesting preprint that fits several recent themes - genome minimization, discontinuation of products - comes from a Japanese grou...
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.